Literature DB >> 2579975

Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

S Koizumi, G A Curt, R L Fine, J D Griffin, B A Chabner.   

Abstract

Immature myeloid precursor cells were preferentially selected from normal human bone marrow by using immune rosette techniques that employed monoclonal antibodies against mature granulocytes, monocytes, T and B lymphocytes, and erythroid precursors (Mo5, M3, OKT3, B1, and EP1, respectively). We examined the formation, retention, and cytotoxic effects of methotrexate (MTX) polyglutamates (MTX-PGs) in these purified myeloid precursor cells. After 1- and 24-h exposures to MTX, with thymidine and deoxyinosine as rescue, the intracellular MTX-PG profile was examined by high-pressure liquid chromatography. Efflux patterns of MTX-PGs were also studied after additional 1- and 24-h incubations in drug-free media. Cytotoxic effects of retained MTX-PGs on bone marrow myeloid precursors were examined by colony formation in drug-free semisolid agar. Normal myeloid precursor cells converted MTX to MTX-PGs in a concentration- and time-dependent manner, preferentially retaining MTX-PGs with three to five glutamyl moieties. At low concentrations of MTX (1 microM), MTX-PG formation was insufficient to maintain saturation of the target enzyme dihydrofolate reductase after removal of drug from the incubation medium, and there was no decrease in myeloid colony formation. At higher concentrations of MTX (10 microM), formation of higher molecular weight polyglutamates was sufficient to allow for 24-h saturation of intracellular binding capacity after removal of extracellular drug and resulted in a 35% reduction in the formation of colony-forming units in culture. Comparison of MTX metabolism in normal bone marrow cells and the MTX-sensitive HL-60 human leukemia cell line showed twofold greater PG formation by these tumor cells after 24-h exposure to 1 or 10 microM MTX, and a marked (greater than 30-fold) increase in cytotoxicity for the HL-60 cells as compared with normal myeloid precursors, suggesting that the MTX polyglutamation may be important to its selective antitumor action.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579975      PMCID: PMC423648          DOI: 10.1172/JCI111761

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Polygammaglutamyl metabolites of methotrexate.

Authors:  C M Baugh; C L Krumdieck; M G Nair
Journal:  Biochem Biophys Res Commun       Date:  1973-05-01       Impact factor: 3.575

3.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

4.  Accumulation of methotrexate diglutamate in human liver during methotrexate therapy.

Authors:  S A Jacobs; C J Derr; D G Johns
Journal:  Biochem Pharmacol       Date:  1977-12-01       Impact factor: 5.858

5.  Monoclonal antibodies detecting antigenic determinants with restricted expression on erythroid cells: from the erythroid committed progenitor level to the mature erythroblast.

Authors:  T Yokochi; M Brice; P S Rabinovitch; T Papayannopoulou; G Stamatoyannopoulos
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

6.  Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer.

Authors:  G A Curt; J Jolivet; B D Bailey; D N Carney; B A Chabner
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

7.  Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.

Authors:  B A Chabner; R C Young
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

8.  Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.

Authors:  V M Whitehead
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

9.  Tissue-specific synthesis of methotrexate polyglutamates in the rat.

Authors:  V M Whitehead; M M Perrault; S Stelcner
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

10.  Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro.

Authors:  I Fabre; G Fabre; I D Goldman
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

View more
  20 in total

1.  The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.

Authors:  Michele Visentin; Ersin Selcuk Unal; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-29       Impact factor: 3.333

2.  Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients.

Authors:  J W O'Callaghan; M J Forrest; P M Brooks
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

3.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

Review 4.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

5.  Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.

Authors:  Goushi Matama; Takaaki Tokito; Hiroaki Takeoka; Yuki Hiraoka; Norikazu Matsuo; Masayuki Nakamura; Hidenobu Ishii; Takashi Kinoshita; Koichi Azuma; Kazuhiko Yamada; Tomoaki Hoshino
Journal:  Invest New Drugs       Date:  2017-03-30       Impact factor: 3.850

6.  Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.

Authors:  Amit Sandhu; Shabeer Ahmad; Jasbinder Kaur; Archana Bhatnagar; Veena Dhawan; Varun Dhir
Journal:  Clin Rheumatol       Date:  2018-07-18       Impact factor: 2.980

7.  Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow.

Authors:  J Baram; C J Allegra; R L Fine; B A Chabner
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.

Authors:  H Schrøder; K Fogh; T Herlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.

Authors:  H Schrøder; K Fogh
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.